계명대학교 의학도서관 Repository

요로계의 전이성 이향상피세포암 환자의 M-VAC(methotrexate, vinblastine, doxorubicin and cisplatin) 병용요법

Metadata Downloads
Author(s)
이경섭박철희이성준Kyung Seop LeeChoal Hee ParkSung Choon Lee
Keimyung Author(s)
Park, Choal HeeLee, Sung Joon
Department
Dept. of Urology (비뇨의학)
Journal Title
대한비뇨기과학회지
Issued Date
1989
Volume
30
Issue
2
Abstract
Patients with advanced urothelial tumors that relapse or persist following conventional therapy have poor prognosis. Management of the patients with recurrent local or disseminated urothelial tumors presents a difficult clinical problems. In 1985 Sternberg et al reported 71% of significant tumor regression and 50% of complete clinical remission with M-VAC (methotrexate, vinblastine, doxorubicin and Cisplatin) combination chemotherapy for treatment of advanced urothelial transitional cell carcinomas. Herein, we have experienced 13 cases of M-VAC combination chemotherapy in advanced urothelial tumors. Complete and partial remission was in achieved 46.2 per cent of the patients clinically, while 15.4 percent had a minor response and 38.4 per cent had progression with median survivals of 11.5, 8.5 and 7.4 months. Toxicity was significant. 15.4 per cent of the patients having experienced nadir sepsis, 30.8 per cent mucositis and 7.6 per cent cardiac toxicity. Median cycle length varied from 31.6 to 41.7 days for the first and 5th cycle respectively. This regimen has been efficacious in selected patients with advanced urothelial tumors.
Alternative Title
M-VAC(Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Urothelial Tumors
Keimyung Author(s)(Kor)
박철희
이성준
Publisher
School of Medicine
Citation
이경섭 et al. (1989). 요로계의 전이성 이향상피세포암 환자의 M-VAC(methotrexate, vinblastine, doxorubicin and cisplatin) 병용요법. 대한비뇨기과학회지, 30(2), 340–344.
Type
Article
ISSN
2005-6737
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/38772
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.